Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 274 articles:
HTML format
Text format



Single Articles


    October 2019
  1. DANG H, Yeo YH, Yasuda S, Huang CF, et al
    Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West.
    Hepatology. 2019 Oct 14. doi: 10.1002/hep.30988.
    PubMed     Text format     Abstract available


  2. LI J, Cheung RC, Nguyen MH
    Chronic hepatitis B and NASH: Is "fat" all bad?
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30983.
    PubMed     Text format     Abstract available


  3. HUANG R, Wang J, Zhang Z, Yan X, et al
    Letter to the Editor: Impact of non-alcoholic steatohepatitis on liver-related outcomes in chronic hepatitis B.
    Hepatology. 2019 Oct 6. doi: 10.1002/hep.30981.
    PubMed     Text format     Abstract available


    September 2019
  4. GOH MJ, Sinn DH, Kim S, Woo SY, et al
    Statin Use and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.
    Hepatology. 2019 Sep 25. doi: 10.1002/hep.30973.
    PubMed     Text format     Abstract available


  5. MURATA K, Tsukuda S, Suizu F, Kimura A, et al
    Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection.
    Hepatology. 2019 Sep 17. doi: 10.1002/hep.30956.
    PubMed     Text format     Abstract available


  6. VERNA EC, Tsapepas D, Emond JC, Brown RS Jr, et al
    Utilization of HCV-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30933.
    PubMed     Text format     Abstract available


    August 2019
  7. BARRE T, Protopopescu C, Bani-Sadr F, Piroth L, et al
    Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30914.
    PubMed     Text format     Abstract available


  8. MAYA S, Ploss A
    Master of disguise: hepatitis delta virus packaging and spread facilitated by diverse viral envelope proteins.
    Hepatology. 2019 Aug 29. doi: 10.1002/hep.30922.
    PubMed     Text format     Abstract available


  9. JOHIRA Y, Hatooka H, Mori N, Fukuhara T, et al
    Regression of idiopathic thrombocytopenic purpura in a patient with eradication of hepatitis C virus by direct-acting antivirals.
    Hepatology. 2019 Aug 20. doi: 10.1002/hep.30900.
    PubMed     Text format     Abstract available


  10. MCCULLOCH K, Romero N, MacLachlan J, Allard N, et al
    Modelling progress towards elimination of hepatitis B in Australia.
    Hepatology. 2019 Aug 16. doi: 10.1002/hep.30899.
    PubMed     Text format     Abstract available


  11. PATRA T, Meyer K, Ray RB, Ray R, et al
    Hepatitis C virus mediated inhibition of miR-181c activates ATM signaling and promotes hepatocyte growth.
    Hepatology. 2019 Aug 10. doi: 10.1002/hep.30893.
    PubMed     Text format     Abstract available


  12. ATCHESON E, Li W, Bliss CM, Chinnakannan S, et al
    Use of an outbred rat hepacivirus challenge model for design and evaluation of efficacy of different immunisation strategies for HCV.
    Hepatology. 2019 Aug 10. doi: 10.1002/hep.30894.
    PubMed     Text format     Abstract available


    July 2019
  13. CHOI HSJ, Brouwer WP, Zanjir WMR, de Man RA, et al
    Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B.
    Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857.
    PubMed     Text format     Abstract available


    June 2019
  14. JONAS MM, Squires RH, Rhee SM, Lin CW, et al
    Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents with Chronic HCV: Part 1 of the DORA Study.
    Hepatology. 2019 Jun 29. doi: 10.1002/hep.30840.
    PubMed     Text format     Abstract available


  15. WONG GL, Wong VW, Yuen BW, Tse YK, et al
    An aging population of chronic hepatitis B with increasing co-morbidities - a territory-wide study from 2000 to 2017.
    Hepatology. 2019 Jun 25. doi: 10.1002/hep.30833.
    PubMed     Text format     Abstract available


  16. LE MH, Yeo YH, Cheung R, Henry L, et al
    Chronic hepatitis B prevalence among foreign-born and US-born adults in the United States, 1999-2016.
    Hepatology. 2019 Jun 22. doi: 10.1002/hep.30831.
    PubMed     Text format     Abstract available


  17. LANG S, Duan Y, Liu J, Torralba MG, et al
    Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis.
    Hepatology. 2019 Jun 22. doi: 10.1002/hep.30832.
    PubMed     Text format     Abstract available


  18. ROSENTHAL P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, et al
    Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30821.
    PubMed     Text format     Abstract available


  19. KANWAL F, Kramer JR, Asch SM, Cao Y, et al
    Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823.
    PubMed     Text format     Abstract available


  20. SCHWARZ KB, Rosenthal P, Murray KF, Honegger JR, et al
    Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830.
    PubMed     Text format     Abstract available


  21. WINER BY, Gaska JM, Lipkowitz G, Bram Y, et al
    Analysis of host responses to hepatitis B and delta viral infections in a micro-scalable hepatic co-culture system.
    Hepatology. 2019 Jun 17. doi: 10.1002/hep.30815.
    PubMed     Text format     Abstract available


    May 2019
  22. OREKONDY N, Cafardi J, Kushner T, Reau N, et al
    HCV in Women and Pregnancy.
    Hepatology. 2019 May 28. doi: 10.1002/hep.30791.
    PubMed     Text format     Abstract available


  23. CHEN HS, Wu JF, Su TH, Chen HL, et al
    Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous HBeAg Seroconversion in HBeAg-Positive Children with a Normal ALT Level.
    Hepatology. 2019 May 23. doi: 10.1002/hep.30788.
    PubMed     Text format     Abstract available


  24. MEHER D, Khatua CR, Singh SP
    Concerns regarding the AARC Study on Corticosteroid therapy for Autoimmune Hepatitis flare causing ACLF.
    Hepatology. 2019 May 23. doi: 10.1002/hep.30787.
    PubMed     Text format     Abstract available


  25. LIN KY, Lin PH, Sun HY, Chen YT, et al
    Hepatitis E Virus Infections Among HIV-Positive Individuals During an Outbreak of Acute Hepatitis A in Taiwan.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30771.
    PubMed     Text format     Abstract available


  26. SUTHERLAND N, Li Wai Suen CFD, Mills C, Lokan J, et al
    Fibrosing cholestatic hepatitis-like syndrome in an immunocompetent patient with an acute flare of chronic hepatitis B.
    Hepatology. 2019 May 11. doi: 10.1002/hep.30763.
    PubMed     Text format     Abstract available


  27. WRENSCH F, Ligat G, Heydmann L, Schuster C, et al
    IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30699.
    PubMed     Text format     Abstract available


    April 2019
  28. JENSEN SB, Fahnoe U, Pham LV, Serre S, et al
    Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30647.
    PubMed     Text format     Abstract available


  29. MARTIN P
    Immunetolerant Hepatitis B: Maybe a misnomer but still hard to treat.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30654.
    PubMed     Text format     Abstract available


  30. JAIN MK, Rich NE, Ahn C, Turner BJ, et al
    Evaluation of a multifaceted intervention to reduce health disparities in hepatitis C screening: a pre-post analysis.
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30638.
    PubMed     Text format     Abstract available


  31. BAKR O, Gelberg L, Seragaki S, Youn S, et al
    Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs.
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30643.
    PubMed     Text format     Abstract available


  32. HOFMEISTER MG, Edlin BR, Rosenberg ES, Rosenthal EM, et al
    Reply to HCV prevalence estimates among incarcerated persons (Letter to the Editor regarding HEP-18-1268.R1).
    Hepatology. 2019 Apr 4. doi: 10.1002/hep.30635.
    PubMed     Text format     Abstract available


  33. YONEJIMA A, Mizukoshi E, Tamai T, Nakagawa H, et al
    Characteristics of impaired dendritic cell function in patients with hepatitis B virus infection.
    Hepatology. 2019 Apr 2. doi: 10.1002/hep.30637.
    PubMed     Text format     Abstract available


  34. SPAULDING AC, Graham CS, Akiyama MJ, Chhatwal J, et al
    HCV prevalence estimates among incarcerated persons.
    Hepatology. 2019 Apr 2. doi: 10.1002/hep.30636.
    PubMed     Text format     Abstract available


    March 2019
  35. FUJIWARA K, Nakano M, Yasui S, Yokosuka O, et al
    Ductular reaction in acute onset autoimmune hepatitis.
    Hepatology. 2019 Mar 22. doi: 10.1002/hep.30621.
    PubMed     Text format     Abstract available


  36. SAHA B, Tornai D, Kodys K, Adejumo A, et al
    Biomarkers of macrophage activation and immune danger signals predict clinical outcomes in alcoholic hepatitis.
    Hepatology. 2019 Mar 19. doi: 10.1002/hep.30617.
    PubMed     Text format     Abstract available


  37. HABIB S
    Letter to Editor: Flare of Autoimmune Hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy.
    Hepatology. 2019 Mar 15. doi: 10.1002/hep.30615.
    PubMed     Text format     Abstract available


    February 2019
  38. REN L, Zeng M, Tang Z, Li M, et al
    The anti-resection activity of the X protein encoded by Hepatitis Virus B.
    Hepatology. 2019 Feb 21. doi: 10.1002/hep.30571.
    PubMed     Text format     Abstract available


  39. JANIK MK, Wunsch E, Raszeja-Wyszomirska J, Krawczyk M, et al
    Depression: An Overlooked Villain in Autoimmune Hepatitis?
    Hepatology. 2019 Feb 17. doi: 10.1002/hep.30568.
    PubMed     Text format     Abstract available


  40. KAMAR N, Pan Q
    No clear evidence for an effect of sofosbuvir against hepatitis E virus in organ-transplant-patients.
    Hepatology. 2019 Feb 5. doi: 10.1002/hep.30546.
    PubMed     Text format     Abstract available


    January 2019
  41. LI T, Liu J, Zhang L, Xu A, et al
    Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: an Important Addition.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30531.
    PubMed     Text format     Abstract available


  42. WANG CC, Kao JH
    The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian chronic hepatitis B patients: friend or foe?
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30532.
    PubMed     Text format     Abstract available


  43. COTTER TG, Paul S, Sandikci B, Couri T, et al
    Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of HCV-Viremic Donors into HCV-Negative Recipients.
    Hepatology. 2019 Jan 31. doi: 10.1002/hep.30540.
    PubMed     Text format     Abstract available


  44. ZEUZEM S, Bourgeois S, Greenbloom S, Buti M, et al
    JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.
    Hepatology. 2019 Jan 28. doi: 10.1002/hep.30527.
    PubMed     Text format     Abstract available


  45. YAN Z, Wu D, Hu H, Zeng J, et al
    Direct inhibition of hepatitis B virus e antigen by core protein allosteric modulator.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30514.
    PubMed     Text format     Abstract available


  46. SAGGERE MURALIKRISHNA S, Kumar Sharma M, Shasthry V, Pande A, et al
    Efficacy of g-csf in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial.
    Hepatology. 2019 Jan 21. doi: 10.1002/hep.30516.
    PubMed     Text format     Abstract available


  47. WU LL, Peng WH, Wu HL, Miaw SC, et al
    Ly6C(+) Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice.
    Hepatology. 2019 Jan 19. doi: 10.1002/hep.30510.
    PubMed     Text format     Abstract available


  48. COYLE C, Moorman AC, Bartholomew T, Klein G, et al
    The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA.
    Hepatology. 2019 Jan 11. doi: 10.1002/hep.30501.
    PubMed     Text format     Abstract available


  49. HUANG SH, Huang CH, Wang NC, Chen TC, et al
    Early seroreversion after 2 doses of hepatitis A vaccination in HIV-positive patients: incidence and associated factors.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30495.
    PubMed     Text format     Abstract available


    December 2018
  50. SEKIBA K, Otsuka M, Ohno M, Yamagami M, et al
    Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus.
    Hepatology. 2018 Dec 26. doi: 10.1002/hep.30491.
    PubMed     Text format     Abstract available


  51. SALMON-CERON D, Nahon P, Layese R, Bourcier V, et al
    HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or end-stage liver disease as compared to HCV mono-infected patients.
    Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400.
    PubMed     Text format     Abstract available


  52. AGUILAR-BRAVO B, Rodrigo-Torres D, Arino S, Coll M, et al
    Ductular reaction cells display an inflammatory profile and recruit neutrophils in alcoholic hepatitis.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30472.
    PubMed     Text format     Abstract available


  53. SOLGA SF, Serper M, Young RA, Forde KA, et al
    Transplantation for Alcoholic Hepatitis: Are We Achieving Justice and Utility?
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30471.
    PubMed     Text format     Abstract available


  54. WU J, Zhou Y, Fu X, Deng M, et al
    The burden of chronic hepatitis C in China from 2004 to 2050: an individual-based modeling study.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30476.
    PubMed     Text format     Abstract available


  55. LIU J, Li T, Zhang L, Xu A, et al
    The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: A Systematic Review.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30474.
    PubMed     Text format     Abstract available


  56. LEE BP, Vittinghoff E, Hsu C, Han H, et al
    Predicting Low-Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The SALT Score.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30478.
    PubMed     Text format     Abstract available


  57. LIN CL, Chu YD, Yeh CT
    Emergence of oncogenic-enhancing hepatitis B virus X gene mutants in patients receiving suboptimal entecavir treatment.
    Hepatology. 2018 Dec 15. doi: 10.1002/hep.30423.
    PubMed     Text format     Abstract available


  58. FELD JJ, Terrault NA, Lin HS, Belle SH, et al
    Entecavir and peginterferon alfa-2a in adults with HBeAg-positive immune tolerant chronic hepatitis B virus infection.
    Hepatology. 2018 Dec 14. doi: 10.1002/hep.30417.
    PubMed     Text format     Abstract available


  59. DRINANE M, Wang XJ, Watt K
    Sofosbuvir and Ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient.
    Hepatology. 2018 Dec 14. doi: 10.1002/hep.30428.
    PubMed     Text format     Abstract available


  60. BUTLER EK, Gersch J, McNamara A, Luk KC, et al
    Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.
    Hepatology. 2018;68:2106-2117.
    PubMed     Text format     Abstract available


    November 2018
  61. HOFMEISTER MG, Rosenthal EM, Barker LK, Rosenberg ES, et al
    Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.
    Hepatology. 2018 Nov 6. doi: 10.1002/hep.30297.
    PubMed     Text format     Abstract available


  62. DAVIS C, Mgomella GS, Filipe ADS, Frost EH, et al
    New highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments.
    Hepatology. 2018 Nov 2. doi: 10.1002/hep.30342.
    PubMed     Text format     Abstract available


  63. WANG YH, Chuang YH, Wu CF, Jan MC, et al
    Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30339.
    PubMed     Text format     Abstract available


    October 2018
  64. MUELLER H, Lopez A, Tropberger P, Wildum S, et al
    PAPD5/7 are novel host factors that are required for Hepatitis B virus RNA stabilization.
    Hepatology. 2018 Oct 26. doi: 10.1002/hep.30329.
    PubMed     Text format     Abstract available


  65. LIU S, Zhou B, Valdes JD, Sun J, et al
    Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection.
    Hepatology. 2018 Oct 25. doi: 10.1002/hep.30325.
    PubMed     Text format     Abstract available


  66. CHEN Y, Hao X, Sun R, Wei H, et al
    NK cell-derived IFN-gamma promotes hepatocellular carcinoma through EpCAM-EMT axis in hepatitis B virus transgenic mice.
    Hepatology. 2018 Oct 17. doi: 10.1002/hep.30317.
    PubMed     Text format     Abstract available


  67. ROSENTHAL P, Ling SC, Belle SH, Murray KF, et al
    Combination of entecavir/ peginterferon alfa-2a in children with HBeAg-positive immune tolerant chronic hepatitis B virus infection.
    Hepatology. 2018 Oct 15. doi: 10.1002/hep.30312.
    PubMed     Text format     Abstract available


  68. PARK H, Wang W, Henry L, Nelson DR, et al
    Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303.
    PubMed     Text format     Abstract available


  69. ZHOU C, Wang W, Mu Y
    Allogeneic Mesenchymal Stem Cells Therapy for the Treatment of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.
    Hepatology. 2018;68:1660-1661.
    PubMed     Text format    


  70. REN JH, Hu JL, Cheng ST, Yu HB, et al
    SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases.
    Hepatology. 2018;68:1260-1276.
    PubMed     Text format     Abstract available


    September 2018
  71. BOESECKE C, Rockstroh JK
    (Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30290.
    PubMed     Text format     Abstract available


  72. YEO YH, Le MH, Chang ET, Henry L, et al
    The prevalence of undetectable vaccine-induced immunity against hepatitis B virus in US adults at high risk for infection.
    Hepatology. 2018 Sep 23. doi: 10.1002/hep.30285.
    PubMed     Text format     Abstract available


  73. ANASTASIOU OE, Widera M, Westhaus S, Timmer L, et al
    Clinical outcome and viral genome variability of hepatitis B virus induced acute liver failure (HEP-18-0579).
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30279.
    PubMed     Text format     Abstract available


  74. SONG ATW, Abdala E, de Martino RB, Malbouisson LMS, et al
    Liver transplantation for fulminant hepatitis due to yellow fever.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30273.
    PubMed     Text format     Abstract available


  75. LIU X, Duan X, Holmes JA, Li W, et al
    A novel lncRNA regulates HCV infection through IFI6.
    Hepatology. 2018 Sep 10. doi: 10.1002/hep.30266.
    PubMed     Text format     Abstract available


  76. KIM JD, Cho EJ, Ahn C, Park SK, et al
    A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure.
    Hepatology. 2018 Sep 8. doi: 10.1002/hep.30262.
    PubMed     Text format     Abstract available


  77. WANG J, Chen J, Liu Y, Zeng X, et al
    Hepatitis B Virus Induces Autophagy to Promote its Replication by the Axis of miR-192-3p-XIAP via NF-kappaB Signaling.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30248.
    PubMed     Text format     Abstract available


  78. KAO WY, Su CW, Tan EC, Lee PC, et al
    Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30247.
    PubMed     Text format     Abstract available


  79. NGUYEN MH, Lim JK, Ozbay AB, Fraysse J, et al
    Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30246.
    PubMed     Text format     Abstract available


  80. SERPER M
    Direct acting antivirals for patients without advanced liver disease: All for treatment and treatment for all?
    Hepatology. 2018;68:804-806.
    PubMed     Text format    


  81. BACKUS LI, Belperio PS, Shahoumian TA, Mole LA, et al
    Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Hepatology. 2018;68:827-838.
    PubMed     Text format     Abstract available


    August 2018
  82. TIAN Y, Ou JJ
    HBV-specific T cells as a Biomarker for Discontinuation of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.
    Hepatology. 2018 Aug 31. doi: 10.1002/hep.30243.
    PubMed     Text format     Abstract available


  83. FOURATI S, Rodriguez C, Hezode C, Soulier A, et al
    Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.
    Hepatology. 2018 Aug 19. doi: 10.1002/hep.30225.
    PubMed     Text format     Abstract available


  84. ANAND L, Choudhury A, Bihari C, Sharma BC, et al
    Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy.
    Hepatology. 2018 Aug 16. doi: 10.1002/hep.30205.
    PubMed     Text format     Abstract available


  85. HOOGEVEEN RC, Lauer GM
    Innocent spectators, helping hands or a fifth column? Acute hepatitis A infection reveals important insights into bystander T cells.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30216.
    PubMed     Text format     Abstract available


  86. RAY RB, Ray R
    Hepatitis C virus manipulates humans as its favorite host for long term relationship.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30214.
    PubMed     Text format     Abstract available


  87. MURRAY KF, Balistreri WF, Bansal S, Whitworth S, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123.
    PubMed     Text format     Abstract available


  88. LI CL, Li CY, Lin YY, Ho MC, et al
    Androgen Receptor Enhances Hepatic TERT Transcription after Hepatitis B Virus Integration or Point Mutation in Promoter Region.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30201.
    PubMed     Text format     Abstract available


  89. MUBARAK G, Ferstenberg R
    The efficacy of Tenofivir to prevent perinatal transmission in chronic hepatitis B mothers'. a clinical perspective.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30138.
    PubMed     Text format     Abstract available


  90. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    PubMed     Text format     Abstract available


  91. TERRAULT N, Brown R Jr, Lok A, Wong J, et al
    Preventing Perinatal Transmission of Hepatitis B Necessitates Consideration of Antiviral Treatment in Pregnancy.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30137.
    PubMed     Text format     Abstract available


  92. REFOLO G, Ciccosanti F, Di Rienzo M, Perdomo AB, et al
    Negative regulation of MAVS-mediated antiviral signaling by the mitochondrial protein LRPPRC during HCV infection.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30149.
    PubMed     Text format     Abstract available


  93. HUSSAINI T, Krajden M, Mitchell RA, Yoshida EM, et al
    Transplanting Hepatitis C seropositive, nucleic acid test negative donor organs into hepatitis C negative recipients.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30121.
    PubMed     Text format     Abstract available


  94. ISHIDA Y, Chung TL, Imamura M, Hiraga N, et al
    Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.
    Hepatology. 2018;68:473-484.
    PubMed     Text format     Abstract available


  95. BLAYA D, Aguilar-Bravo B, Hao F, Casacuberta-Serra S, et al
    Expression of microRNA-155 in inflammatory cells modulates liver injury.
    Hepatology. 2018;68:691-706.
    PubMed     Text format     Abstract available


    July 2018
  96. GOLDEN-MASON L, Rosen HR
    Revisiting the Paradox of ISG expression as a predictor of HCV treatment response, a decade later.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30195.
    PubMed     Text format     Abstract available


  97. VINIKOOR MJ, Sinkala E, Chihota B, Kanunga A, et al
    Hepatitis B therapy as HIV prevention in Africa: a case series from Zambia.
    Hepatology. 2018 Jul 18. doi: 10.1002/hep.30183.
    PubMed     Text format     Abstract available


  98. JAIN MK, Thamer M, Therapondos G, Shiffman ML, et al
    Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30171.
    PubMed     Text format     Abstract available


  99. TUCCI F, Calbi V, Barzaghi F, Migliavacca M, et al
    Successful treatment with Harvoni((R)) in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis((R)).
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30160.
    PubMed     Text format     Abstract available


  100. CHU CM, Liaw YF
    Age at HBeAg seroconversion and other factors for outcomes of chronic hepatitis B.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30179.
    PubMed     Text format     Abstract available


    June 2018
  101. HAYASHI S, Khan A, Simons BC, Homan C, et al
    A novel association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan Native People.
    Hepatology. 2018 Jun 12. doi: 10.1002/hep.30111.
    PubMed     Text format     Abstract available


  102. MARTINS PN
    Transplantation of Livers from Viremic HCV Positive Donors into HCV Negative Recipients.
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30106.
    PubMed     Text format    


  103. QUINET J, Jamard C, Burtin M, Lemasson M, et al
    Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
    Hepatology. 2018;67:2127-2140.
    PubMed     Text format     Abstract available


    May 2018
  104. LIU N, Liu Q, Yang X, Zhang F, et al
    Hepatitis B virus-upregulated lnc-HUR1 promotes cell proliferation and tumorigenesis by blocking p53 activity.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30098.
    PubMed     Text format     Abstract available


  105. COURI T, Gupta T, Weyer G, Aronsohn A, et al
    Pay It Forward: Building Capacity to Treat Hepatitis C by Training Our Own Residents.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30101.
    PubMed     Text format    


  106. SALAM KA, Wang RY, Grandinetti T, De Giorgi V, et al
    Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30087.
    PubMed     Text format     Abstract available


  107. ZHANG H, Zhang C, Tang H, Gao S, et al
    CD2-associated Protein Contributes to Hepatitis C Virus Propagation and Steatosis by Disrupting Insulin Signaling.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30073.
    PubMed     Text format     Abstract available


  108. MANSKE K, Kallin N, Konig V, Schneider A, et al
    Outcome of anti-viral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30080.
    PubMed     Text format     Abstract available


  109. WANG C, Cheng Y, Zhang X, Li N, et al
    Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30077.
    PubMed     Text format     Abstract available


    April 2018
  110. ALAO H, Cam M, Keembiyehetty C, Zhang F, et al
    Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.29921.
    PubMed     Text format     Abstract available


  111. LIM TY, Martinez-Llordella M, Kodela E, Gray E, et al
    Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30059.
    PubMed     Text format    


  112. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    PubMed     Text format    


  113. WIRTH S, Zhang H, Hardikar W, Schwarz KB, et al
    Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children with Chronic Hepatitis B: The PEG-B-ACTIVE Study.
    Hepatology. 2018 Apr 24. doi: 10.1002/hep.30050.
    PubMed     Text format     Abstract available


  114. VERRIER ER, Yim SA, Heydmann L, El Saghire H, et al
    Hepatitis B virus evasion from cGAS sensing in human hepatocytes.
    Hepatology. 2018 Apr 20. doi: 10.1002/hep.30054.
    PubMed     Text format     Abstract available


  115. CHOLANKERIL G, Gadiparthi C, Kim D, Ahmed A, et al
    Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30043.
    PubMed     Text format    


  116. TERRAULT NA
    Hepatitis C in Patients with Renal Disease: A Deeper Dive into the KDIGO Guideline.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30047.
    PubMed     Text format    


  117. REAU N, Kwo PY, Rhee S, Brown RS Jr., et al
    Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046.
    PubMed     Text format     Abstract available


  118. CHHATWAL J, Bethea ED, Samur S, Chung RT, et al
    Reply to Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30042.
    PubMed     Text format    


  119. KWONG AJ, Kim WR, Flemming JA
    De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30045.
    PubMed     Text format     Abstract available


  120. WONG LL, Fisher HF, Stocken DD, Rice S, et al
    The Impact of Autoimmune Hepatitis and its Treatment on Health Utility.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30031.
    PubMed     Text format     Abstract available


  121. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    PubMed     Text format     Abstract available


  122. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Text format     Abstract available


  123. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    PubMed     Text format     Abstract available


  124. XIE L, Yin J, Xia R, Zhuang G, et al
    Cost-effectiveness of antiviral treatment after resection in HBV-related hepatocellular carcinoma patients with compensated cirrhosis.
    Hepatology. 2018 Apr 7. doi: 10.1002/hep.29922.
    PubMed     Text format     Abstract available


  125. PERLEMUTER G
    Circulating bugs in blood in alcoholic liver disease!
    Hepatology. 2018;67:1207-1209.
    PubMed     Text format    


    March 2018
  126. FAILLACI F, Marzi L, Critelli R, Milosa F, et al
    Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29911.
    PubMed     Text format     Abstract available


  127. GUO JT, Block TM
    Do hepatitis B surface antigens have any role in viral carcinogenesis?
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29886.
    PubMed     Text format    


  128. RAMAMURTHY N, Marchi E, Ansari MA, Pedergnana V, et al
    Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877.
    PubMed     Text format     Abstract available


  129. NISHIDA N, Sugiyama M, Sawai H, Nishina S, et al
    Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29876.
    PubMed     Text format     Abstract available


  130. FUNG J, Cheung KS, Wong DK, Mak LY, et al
    Long Term Outcomes and Predictive Scores for Hepatocellular Carcinoma and HBsAg Seroclearance after HBeAg Seroclearance.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29874.
    PubMed     Text format     Abstract available


  131. VAN CAMPENHOUT MJH, van Bommel F, Pfefferkorn M, Fischer J, et al
    Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.
    Hepatology. 2018 Mar 7. doi: 10.1002/hep.29872.
    PubMed     Text format     Abstract available


    February 2018
  132. HUANG AC, Mehta N, Dodge JL, Yao FY, et al
    Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout.
    Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855.
    PubMed     Text format     Abstract available


  133. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    PubMed     Text format     Abstract available


  134. KWON YC, Meyer K, Peng G, Chatterjee S, et al
    Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29843.
    PubMed     Text format     Abstract available


  135. DOI A, Hikita H, Sakamori R, Tahata Y, et al
    NS5A-P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29836.
    PubMed     Text format    


  136. SMITH D, Magri A, Bonsall D, Ip CL, et al
    Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29837.
    PubMed     Text format     Abstract available


  137. TERRAULT NA, Lok AS, McMahon BJ, Chang KM, et al
    Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.
    Hepatology. 2018 Feb 5. doi: 10.1002/hep.29800.
    PubMed     Text format    


  138. ATKINSON SR, McQuillin A, Morgan MY, Thursz MR, et al
    People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol.
    Hepatology. 2018 Feb 2. doi: 10.1002/hep.29825.
    PubMed     Text format    


    January 2018
  139. LAMPERTICO P, Berg T
    Less can be more - a finite treatment approach for HBeAg-negative chronic hepatitis B.
    Hepatology. 2018 Jan 30. doi: 10.1002/hep.29821.
    PubMed     Text format    


  140. BERENGUER J, Gil-Martin A, Jarrin I, Moreno A, et al
    All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29814.
    PubMed     Text format     Abstract available


  141. HORST AK, Wegscheid C, Schaefers C, Schiller B, et al
    CEACAM1 controls IL-2-dependent regulatory T cell induction in immune-mediated hepatitis.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29812.
    PubMed     Text format     Abstract available


  142. ETZION O
    Treatment for Hepatitis Delta Virus with the Prenylation Inhibitor lonafranib: It's Getting Closer.
    Hepatology. 2018 Jan 24. doi: 10.1002/hep.29807.
    PubMed     Text format    


  143. LO GH
    Does antiplatelet therapy really reduce the risk of hepatocellular carcinoma in hepatitis B patients with antiviral drug?
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29794.
    PubMed     Text format    


  144. MARTINI S, Caccamo L, Rizzetto M
    Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D?
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29796.
    PubMed     Text format    


  145. YEN CJ, Ai YL, Tsai HW, Chan SH, et al
    Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29790.
    PubMed     Text format     Abstract available


  146. INOUE J, Ninomiya M, Shimosegawa T, McNiven MA, et al
    Cellular membrane trafficking machineries utilized by the hepatitis viruses.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29785.
    PubMed     Text format     Abstract available


  147. LIN KY, Hsieh SM, Sun HY, Lo YC, et al
    Serologic Responses and Effectiveness of Hepatitis A Vaccination Among HIV-Positive Individuals During the Outbreak of Acute Hepatitis A.
    Hepatology. 2018 Jan 12. doi: 10.1002/hep.29780.
    PubMed     Text format     Abstract available


  148. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Response to Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29770.
    PubMed     Text format    


  149. CONGLY SE, Lee SS
    Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29771.
    PubMed     Text format    


  150. ZHANG H, Lian M, Zhang J, Bian Z, et al
    A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation.
    Hepatology. 2018;67:232-246.
    PubMed     Text format     Abstract available


  151. HERRMANN E, de Ledinghen V, Cassinotto C, Chu WC, et al
    Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.
    Hepatology. 2018;67:260-272.
    PubMed     Text format     Abstract available


    December 2017
  152. GRAKOUI A, Walker CM
    Of mice, rats and men: Small animal model of hepatitis C virus infection.
    Hepatology. 2017 Dec 27. doi: 10.1002/hep.29765.
    PubMed     Text format    


  153. SU TH, Tseng TC, Kao JH
    HCC risk in patients with HBV-related cirrhosis receiving NA therapy: is HCC prevented or delayed?
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29740.
    PubMed     Text format    


  154. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed     Text format    


  155. WANG S, Wang H, Ding WX
    Pyroptosis, a Novel Player for Alcoholic Hepatitis?
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29725.
    PubMed     Text format    


  156. CHHATWAL J, Samur S, Bethea ED, Ayer T, et al
    Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29723.
    PubMed     Text format     Abstract available


  157. XU C, Zhang C, Ji J, Wang C, et al
    CD36 Deficiency Attenuates Immune-Mediated Hepatitis in Mice by Modulating the Proapoptotic Effects of CXCL10.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29716.
    PubMed     Text format     Abstract available


  158. BARI K, Luckett K, Kaiser T, Diwan T, et al
    Hepatitis C Transmission from Seropositive, Non-Viremic Donors to Non-Hepatitis C Liver Transplant Recipients.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29704.
    PubMed     Text format     Abstract available


  159. LI DK, Ren Y, Fierer DS, Rutledge S, et al
    The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29707.
    PubMed     Text format     Abstract available


  160. SORIA A, Lapadula G, Fabbiani M, Gori A, et al
    Lower effectiveness of hepatitis C antiviral treatment in patients with hepatocellular carcinoma: Is active tumor the clue?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29700.
    PubMed     Text format    


  161. WANG W, Wang Y, Qu C, Wang S, et al
    The RNA genome of hepatitis E virus robustly triggers antiviral interferon response.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29702.
    PubMed     Text format     Abstract available


  162. JI F, Yeo YH, Wei MT, Wei B, et al
    Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29701.
    PubMed     Text format    


  163. GERMANIDIS G, Hytiroglou P, Vassiliadis T, Speletas M, et al
    Checkpoint modulation in chronic hepatitis B: From hypothesis to approval.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29695.
    PubMed     Text format    


  164. HARRINGTON PR, Komatsu TE, Deming DJ, Donaldson EF, et al
    Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29693.
    PubMed     Text format     Abstract available


  165. ALNUAIMI K, Lavole J, Lascoux-Combes C, Afonso AR, et al
    Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29697.
    PubMed     Text format    


  166. CHEN X, Oidovsambuu O, Liu P, Grosely R, et al
    A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.
    Hepatology. 2017;66:1739-1749.
    PubMed     Text format     Abstract available


    November 2017
  167. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Global micro RNA expression profiling in the liver biopsies of Hepatitis B Virus infected patients suggests specific miRNA signatures for viral persistence and hepatocellular injury.
    Hepatology. 2017 Nov 30. doi: 10.1002/hep.29690.
    PubMed     Text format     Abstract available


  168. SAAB S, Le L, Saggi S, Sundaram V, et al
    Towards the Elimination of Hepatitis C in the United States.
    Hepatology. 2017 Nov 27. doi: 10.1002/hep.29685.
    PubMed     Text format     Abstract available


  169. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed     Text format    


  170. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed     Text format    


  171. POORDAD F, Pol S, Asatryan A, Buti M, et al
    Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671.
    PubMed     Text format     Abstract available


  172. KALAL C, Shukla A, Mohanka R, Vora M, et al
    Sofosbuvir, Peg Interferon & Ribavirin for retreatment of HCV genotype 1b following Sofosbuvir and Ledipasvir failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29667.
    PubMed     Text format    


  173. YURDAYDIN C, Keskin O, Kalkan C, Karakaya F, et al
    Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The lowr HDV - 1 study.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29658.
    PubMed     Text format     Abstract available


  174. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed     Text format    


  175. CHAUHAN A, Adams DH
    Exercise alters the hepatic immunophenotype to protect against inflammatory liver disease.
    Hepatology. 2017 Nov 16. doi: 10.1002/hep.29657.
    PubMed     Text format    


  176. JENG WJ, Chen YC, Chien RN, Sheen IS, et al
    Incidence and predictors of HBsAg seroclearance after cessation of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29640.
    PubMed     Text format     Abstract available


  177. KHANOVA E, Wu R, Wang W, Yan R, et al
    Pyroptosis by Caspase11/4-Gasdermin-D Pathway in Alcoholic Hepatitis.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29645.
    PubMed     Text format     Abstract available


  178. SIKAVI C, Chen PH, Lee AD, Saab EG, et al
    Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642.
    PubMed     Text format     Abstract available


    October 2017
  179. PURI P, Liangpunsakul S, Christensen JE, Shah VH, et al
    The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.
    Hepatology. 2017 Oct 30. doi: 10.1002/hep.29623.
    PubMed     Text format     Abstract available


  180. LIU J
    Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals.
    Hepatology. 2017 Oct 28. doi: 10.1002/hep.29620.
    PubMed     Text format    


  181. SHEN F, Li Y, Yang Wang, Sozzi V, et al
    Hepatitis B Virus Sensitivity to Interferon-alpha in Hepatocytes is More Associated with Cellular Interferon Response than with Viral Genotype.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29609.
    PubMed     Text format     Abstract available


  182. STRUBLE K, Chan-Tack K, Qi K, Naeger LK, et al
    Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV genotype: FDA's Evaluation.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29601.
    PubMed     Text format     Abstract available


  183. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611.
    PubMed     Text format     Abstract available


  184. KUSHNER T, Shinkai K, Fox L, Ying D, et al
    New Presentation of Autoimmune Hepatitis with Erythema Multiforme.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29610.
    PubMed     Text format    


  185. YOUNOSSI ZM
    The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29580.
    PubMed     Text format    


  186. GONZALEZ SA, Trotter JF
    The Rise of the Opioid Epidemic and Hepatitis C Positive Organs: A New Era in Liver Transplantation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29572.
    PubMed     Text format     Abstract available


  187. BIAN Y, Zhang Z, Sun Z, Zhao J, et al
    Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
    Hepatology. 2017;66:1067-1082.
    PubMed     Text format     Abstract available


  188. CAO Z, Liu Y, Ma L, Lu J, et al
    A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
    Hepatology. 2017;66:1058-1066.
    PubMed     Text format     Abstract available


    September 2017
  189. KAMILI S, Drobeniuc J, Mixson-Hayden T, Kodani M, et al
    Delta Hepatitis: Towards Improved Diagnostics.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29564.
    PubMed     Text format    


  190. NIMGAONKAR I, Ploss A
    A porcine model for chronic hepatitis E.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29566.
    PubMed     Text format    


  191. MAUGE L, Pavie J, Batisse D, Darnige L, et al
    Acquired hemophilia A resolution in an HCV/HIV coinfected patient with cure of hepatitis C by direct antiviral agents.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29560.
    PubMed     Text format    


  192. CHTIOUI H
    OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29556.
    PubMed     Text format    


  193. AHMED A, Beckerman R, Younossi ZM
    Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29555.
    PubMed     Text format    


  194. MAURO E, Crespo G, Montironi C, Londono MC, et al
    Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29557.
    PubMed     Text format     Abstract available


  195. PHILIPS CA, Augustine P
    Plasma biomarkers to diagnose alcoholic hepatitis - are we there yet?
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29547.
    PubMed     Text format    


  196. YARTEL AK, Rein DB, Ann Brown K, Krauskopf K, et al
    Hepatitis C Virus Testing for Case Identification in Persons Born during 1945-1965: Results from Three Randomized Controlled Trials.
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29548.
    PubMed     Text format     Abstract available


  197. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Text format     Abstract available


  198. VIONNET J, Pascual M, Testoni B, Combet C, et al
    Late hepatitis B reactivation following DAA-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29528.
    PubMed     Text format    


  199. LEE MH, Huang YH, Chen HY, Khor CS, et al
    Human Leukocyte Antigen Variants and Risk of Hepatocellular Carcinoma Modified by HCV Genotypes: A Genome-wide Association Study.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29531.
    PubMed     Text format     Abstract available


  200. ALTER H, Block TM, Brown N, Brownstein A, et al
    A Research Agenda for Curing Chronic Hepatitis B Virus Infection.
    Hepatology. 2017 Sep 6. doi: 10.1002/hep.29509.
    PubMed     Text format    


  201. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed     Text format    


  202. PARK H, Chen C, Wang W, Henry L, et al
    Chronic Hepatitis C Increases the Risk of Chronic Kidney Disease (CKD) while Effective HCV Treatment Decreases the Incidence of CKD.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29505.
    PubMed     Text format     Abstract available


  203. TOYODA H, Chayama K, Suzuki F, Sato K, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29510.
    PubMed     Text format     Abstract available


    August 2017
  204. MANATSATHIT W, Samant H, Nakayuenyongsuk W
    Mesenchymal stem cells for hepatitis B patients with acute on chronic liver failure-Are we there?
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29493.
    PubMed     Text format    


  205. TRIVEDI S, Murthy S, Sharma H, Hartlage AS, et al
    Viral persistence, liver disease and host response in Hepatitis C-like virus rat model.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29494.
    PubMed     Text format     Abstract available


  206. PAPATHEODORIDIS GV, Manolakopoulos S, Su TH, Siakavellas S, et al
    Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29497.
    PubMed     Text format     Abstract available


  207. MATTINGLY TJ 2ND, Perfetto EM, Johnson S
    Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29482.
    PubMed     Text format     Abstract available


  208. HONG X, Kim ES, Guo H
    Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B.
    Hepatology. 2017 Aug 18. doi: 10.1002/hep.29479.
    PubMed     Text format     Abstract available


  209. HALGAND B, Desterke C, Riviere L, Fallot G, et al
    Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29463.
    PubMed     Text format     Abstract available


  210. INNES H, McAuley A, Alavi M, Valerio H, et al
    The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: A population cohort-study.
    Hepatology. 2017 Aug 4. doi: 10.1002/hep.29419.
    PubMed     Text format     Abstract available


  211. KRISS M, Burchill M
    HCV and non-hepatic malignancy: Is pre-emptive DAA therapy indicated prior to treatment?
    Hepatology. 2017 Aug 2. doi: 10.1002/hep.29414.
    PubMed     Text format    


  212. LOK AS, Zoulim F, Dusheiko G, Ghany MG, et al
    Hepatitis B cure: From discovery to regulatory approval.
    Hepatology. 2017 Aug 1. doi: 10.1002/hep.29323.
    PubMed     Text format     Abstract available


    July 2017
  213. COBB DA, Golden-Mason L, Rosen HR, Hahn YS, et al
    Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during HCV infection.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29409.
    PubMed     Text format     Abstract available


  214. LI G, Zhu Y, Shao D, Chang H, et al
    Recombinant cccDNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29406.
    PubMed     Text format     Abstract available


  215. KONDILI LA, Romano F, Rolli FR, Ruggeri M, et al
    Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29399.
    PubMed     Text format     Abstract available


  216. LUCEY MR
    Redefining successful treatment of severe alcoholic hepatitis.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29398.
    PubMed     Text format    


  217. ROSEN HR, Ghany M, Chung R, Lok A, et al
    NAM 2017 Report: A National Plan To Eliminate Hepatitis B and C In the United States By 2030 And The AASLD's Response.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29361.
    PubMed     Text format    


  218. KONERMAN MA, Thomson M, Gray K, Moore M, et al
    Impact of an Electronic Health Record Alert in Primary Care on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29362.
    PubMed     Text format     Abstract available


  219. PERSICO M, Aglitti A, Caruso R, De Renzo A, et al
    Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29364.
    PubMed     Text format     Abstract available


  220. LOK AS, Chung RT, Vargas HE, Kim AY, et al
    Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Hepatology. 2017 Jul 16. doi: 10.1002/hep.29366.
    PubMed     Text format    


  221. HUANG YH, Lee SD
    Is antibody to surface antigen associated with hepatitis B reactivation in patients with resolved hepatitis B?
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29357.
    PubMed     Text format    


  222. WYLES D, Wedemeyer H, Ben-Ari Z, Gane EJ, et al
    Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29358.
    PubMed     Text format     Abstract available


  223. SIMONETTO DA, Kamath PS, Shah VH
    Alcoholic Hepatitis: Continued drinking and the mourning after.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29349.
    PubMed     Text format    


  224. LIN BL, Chen JF, Qiu WH, Wang KW, et al
    Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial.
    Hepatology. 2017;66:209-219.
    PubMed     Text format     Abstract available


    June 2017
  225. CHENG X, Xia Y, Serti E, Block PD, et al
    Hepatitis B virus evades innate immunity of hepatocytes but activates macrophages during infection.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.
    PubMed     Text format     Abstract available


  226. SASAKI R, Devhare P, Ray RB, Ray R, et al
    Hepatitis C virus induced tumor initiating cancer stem-like cells activate stromal fibroblasts in xenograft tumor model.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29346.
    PubMed     Text format     Abstract available


  227. TORRES HA, Hosry J, Mahale P, Economides MP, et al
    Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29344.
    PubMed     Text format     Abstract available


  228. SISE M
    Kidney transplant recipients with Hepatitis C virus experienced 100% SVR12 rate when treated with sofosbuvir-ledipasvir.
    Hepatology. 2017 Jun 26. doi: 10.1002/hep.29339.
    PubMed     Text format    


  229. ALTAMIRANO J, Lopez-Pelayo H, Michelena J, Jones PD, et al
    Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29338.
    PubMed     Text format     Abstract available


  230. CHOI J, Han S, Kim N, Lim YS, et al
    Increasing Burden of Liver Cancer Despite Extensive Use of Antiviral Agents in a Hepatitis B Virus-Endemic Population.
    Hepatology. 2017 Jun 19. doi: 10.1002/hep.29321.
    PubMed     Text format     Abstract available


  231. PAPATHEODORIDIS GV, Idilman R, Dalekos GN, Buti M, et al
    The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29320.
    PubMed     Text format     Abstract available


  232. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Text format     Abstract available


  233. LEE M, Chung GE, Lee JH, Oh S, et al
    Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.
    Hepatology. 2017 Jun 15. doi: 10.1002/hep.29318.
    PubMed     Text format     Abstract available


  234. FALADE-NWULIA O, Sutcliffe C, Moon J, Chander G, et al
    High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29308.
    PubMed     Text format     Abstract available


  235. GAO Y, Feng J, Yang G, Zhang S, et al
    HBx-elevated MSL2 Modulates HBV cccDNA through Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29316.
    PubMed     Text format     Abstract available


  236. LIBERAL R, Grant CR, Yuksel M, Graham J, et al
    Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29307.
    PubMed     Text format     Abstract available


  237. CHHATWAL J, Samur S, Bethea E, Chung RT, et al
    Response to Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29299.
    PubMed     Text format    


  238. CHOLANKERIL G, Wong RJ, Kim D, Ahmed A, et al
    Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29300.
    PubMed     Text format    


    May 2017
  239. GANE E
    Is HBIG still needed after liver transplantation for CHB?
    Hepatology. 2017 May 26. doi: 10.1002/hep.29292.
    PubMed     Text format    


  240. WIRTH S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, et al
    Sofosbuvir and Ribavirin in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29278.
    PubMed     Text format     Abstract available


  241. SAXENA V, Khungar V, Verna EC, Levitsky J, et al
    Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29258.
    PubMed     Text format     Abstract available


  242. GANE EJ, Shiffman ML, Etzkorn K, Morelli G, et al
    Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29256.
    PubMed     Text format     Abstract available


  243. WANG CC, Kao JH
    Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
    Hepatology. 2017 May 8. doi: 10.1002/hep.29252.
    PubMed     Text format    


  244. MAILLY L, Zeisel MB, Baumert TF
    Towards novel immunocompetent animal models for hepatitis B virus infection.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29249.
    PubMed     Text format    


  245. LI W, Amet T, Xing Y, Yang D, et al
    Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29242.
    PubMed     Text format     Abstract available


  246. REN YD, Ye ZS, Yang LZ, Jin LX, et al
    Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy.
    Hepatology. 2017;65:1765-1768.
    PubMed     Text format    


    April 2017
  247. LOUVET A, Labreuche J, Artru F, Bouthors A, et al
    Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis: A prospective study.
    Hepatology. 2017 Apr 29. doi: 10.1002/hep.29240.
    PubMed     Text format     Abstract available


  248. DIAB AM, Foca A, Fusil F, Lahlali T, et al
    Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication.
    Hepatology. 2017 Apr 26. doi: 10.1002/hep.29236.
    PubMed     Text format     Abstract available


  249. MIN AD
    Low-level viremia in hepatitis B patients on antiviral treatment: Can we ignore it?
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29235.
    PubMed     Text format    


  250. BARGE S, Ziol M, Nault JC
    Autoimmune-like chronic hepatitis induced by olmesartan.
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29228.
    PubMed     Text format     Abstract available


  251. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    PubMed     Text format    


  252. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Text format     Abstract available


  253. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed     Text format    


  254. MERLI M, Frigeni M, Gotti M, Grossi P, et al
    Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29198.
    PubMed     Text format    


  255. CHANG ML, Liaw YF
    Overt acute hepatitis B is more severe in female patients.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29196.
    PubMed     Text format    


  256. LAI TS, Lee MH, Yang HI, You SL, et al
    Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29192.
    PubMed     Text format     Abstract available


  257. FORREST E
    Clinical Criteria are Critical to Diagnosing Alcoholic Hepatitis.
    Hepatology. 2017 Apr 1. doi: 10.1002/hep.29188.
    PubMed     Text format    


    March 2017
  258. FUNG J, Wong T, Chok K, Chan A, et al
    Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years.
    Hepatology. 2017 Mar 31. doi: 10.1002/hep.29191.
    PubMed     Text format     Abstract available


  259. LIM YS, Lee YS, Gwak GY, Byun KS, et al
    Monotherapy with Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29187.
    PubMed     Text format     Abstract available


  260. PERRILLO RP
    HBV Reactivation During DAA Treatment of Chronic Hepatitis C: A Hidden Danger of an Otherwise Major Success Story.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29185.
    PubMed     Text format    


  261. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    PubMed     Text format    


  262. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    PubMed     Text format     Abstract available


  263. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  264. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed     Text format    


  265. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Text format     Abstract available


  266. AHMED A, Gonzalez SA, Cholankeril G, Perumpail RB, et al
    Treatment of Patients Waitlisted for Liver Transplant with an All-Oral DAAs is a Cost-Effective Treatment Strategy in the United States.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29137.
    PubMed     Text format     Abstract available


    February 2017
  267. GOLDEN-MASON L, Rosen HR
    Galectin-9: Diverse Roles in Hepatic Immune Homeostasis and Inflammation.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29106.
    PubMed     Text format     Abstract available


  268. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Text format     Abstract available


    January 2017
  269. STEINMETZ C, Kashyap A, Zhivkova N, Alizor H, et al
    Activation of SIRT1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29072.
    PubMed     Text format     Abstract available


  270. BAECHLEIN C, Becher P
    No evidence for zoonotic hepatitis E virus infection through dairy milk in Germany.
    Hepatology. 2017;65:394-395.
    PubMed     Text format    


    December 2016
  271. AYUBI E, Safiri S, Sani M, Doosti-Irani A, et al
    Effect of Metabolic syndrome on cardiovascular, hepatic events and death in CHB patients: Methodological issues.
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.29001.
    PubMed     Text format    


    November 2016
  272. FLEMMING JA, Kim WR, Brosgart CL, Terrault NA, et al
    Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28923.
    PubMed     Text format     Abstract available


  273. KIM JH, Sinn DH, Kang W, Gwak GY, et al
    Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28916.
    PubMed     Text format     Abstract available


    October 2016
  274. LABONTE AC, Sung SJ, Jennelle LT, Dandekar AP, et al
    Expression of scavenger receptor-AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28873.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: